A Phase II trial, known as the ARISTOCRAT study, is currently underway to expand an earlier clinical study [39] to evaluate the efficacy of nabiximols (a 1:1 mixture of THC and CBD) in combination with TMZ in patients with MGMT‐methylated recurrent GBM [78]. Here, MGMT is linked to glioblastoma.